Fino 20 Tablet 1 Strip

✔️ Dosage and Administration

The recommended starting dose depends on the patient's eGFR and serum potassium level. The usual target dose is 20 mg once daily, provided potassium levels and kidney function allow safe treatment.

Recommended starting dose based on eGFR:

• eGFR ≥60 mL/min/1.73 m²: 20 mg orally once daily.
• eGFR ≥25 to less than 60 mL/min/1.73 m²: 10 mg orally once daily.
• eGFR below 25 mL/min/1.73 m²: Initiation of treatment is not recommended.

The dose may be increased after four weeks, depending on serum potassium and kidney function, to reach 20 mg once daily when appropriate.

• Children: The safety and effectiveness of finerenone have not been established in patients younger than 18 years.
• Older adults: No routine dose adjustment is generally required solely because of age. Kidney function, potassium levels, and overall clinical status should guide treatment.
• Hepatic impairment: Finerenone should be avoided in patients with severe hepatic impairment (Child-Pugh class C). Dose adjustment is generally unnecessary in mild or moderate hepatic impairment, although additional potassium monitoring may be appropriate in moderate impairment.
• Renal impairment: The starting dose is determined by eGFR. Treatment initiation is not recommended when eGFR is below 25 mL/min/1.73 m².

Finerenone can be taken with or without food. If swallowing a tablet is difficult, it may be crushed and mixed with water or soft food, according to the product instructions.

✔️ Side Effects:

Adverse reactions reported more frequently with finerenone than with placebo include:

• Hyperkalemia (high potassium levels in the blood)
• Hypotension (low blood pressure)
• Hyponatremia (low sodium levels in the blood)

✔️ Monitoring and Dose Adjustment

Measure serum potassium and eGFR before starting treatment. Do not initiate finerenone if serum potassium is above 5.0 mEq/L.

Check serum potassium approximately four weeks after starting treatment and again four weeks after any dose adjustment. Continue periodic monitoring throughout treatment, with more frequent testing when clinically necessary.

If potassium levels rise, the dose may need to be reduced or treatment temporarily withheld according to the prescribing guidelines.

✔️ Pregnancy & Lactation (গর্ভাবস্থা ও দুগ্ধদান):

Pregnancy: There are limited human data regarding finerenone use during pregnancy. Animal studies have reported developmental effects at exposures higher than those expected with standard human dosing. Use during pregnancy should be discussed with a healthcare professional after carefully assessing potential risks and benefits.

Breastfeeding: It is not known whether finerenone or its metabolites pass into human breast milk. Because of the potential risk to a breastfed infant, breastfeeding should be avoided during treatment and for one day after the last dose, according to the prescribing information.

✔️ Safety Information:

• Finerenone may cause hyperkalemia, particularly in patients with reduced kidney function, elevated baseline potassium levels, or other risk factors.
• Check serum potassium and eGFR before treatment and periodically afterward.
• Do not start treatment if serum potassium exceeds 5.0 mEq/L.
• Monitor potassium more closely when taking other medicines that increase potassium levels or reduce its excretion.
• Inform your doctor about existing kidney disease, liver disease, or any history of abnormal potassium levels.
• Follow the prescribed dose and laboratory monitoring schedule.

✔️ Interaction

• Strong CYP3A4 inhibitors: These medicines can increase finerenone concentrations and the risk of adverse effects. Concomitant use is contraindicated.
• Moderate and weak CYP3A4 inhibitors: These may increase finerenone exposure. Serum potassium should be monitored when either medicine is started or its dose is changed.
• Strong and moderate CYP3A4 inducers: These may reduce finerenone concentrations and effectiveness. Concomitant use should be avoided.
• Grapefruit: Avoid grapefruit and grapefruit juice during treatment because they may affect CYP3A4 activity and increase finerenone exposure.

✔️ Storage Conditions

Store below 30°C, protected from light and moisture. Keep out of reach of children.